Fixed-dose combination rosiglitazone/glimepiride in the treatment of Type 2 diabetes mellitus

Giuseppe Derosa, Sibilla A T Salvadeo, Arrigo F G Cicero

Research output: Contribution to journalArticlepeer-review


Rosiglitazone and glimepiride are effective antihyperglycemic agents approved for the treatment of Type 2 diabetes mellitus. Primarily, rosiglitazone increases insulin sensitivity, while glimepiride stimulates insulin release from β-cells in the pancreas. Combination therapy is often required to achieve effective glycemic control. A fixed-dose formulation of rosiglitazone plus glimepiride has recently been approved in the EU and US for treatment of Type 2 diabetes. Much data demonstrate the advantages of the combination therapy compared with rosiglitazone or glimepiride as monotherapy. Rosiglitazone plus glimepiride is generally well tolerated in all studies and presents a tolerability profile similar to that of monotherapy with rosiglitazone and sulphonylurea. The aim of this review is to present this new fixed-dose combination, which represents a promising new strategy to obtain recommended glycemic control.

Original languageEnglish
Pages (from-to)559-569
Number of pages11
Issue number5
Publication statusPublished - Sep 2006


  • Glimepiride
  • Glycemic control
  • PPAR-γ
  • Rosiglitazone
  • Sulphonyurea
  • Thiazolidinediones

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Fixed-dose combination rosiglitazone/glimepiride in the treatment of Type 2 diabetes mellitus'. Together they form a unique fingerprint.

Cite this